2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Vaccines, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Platelet Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MPN, CML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

1971 Selective PIM1 inhibition with nuvisertib promotes megakaryocyte maturation and platelet production in myelofibrosis patients

Lilian Varricchio, PhD, Gohar Mosoyan2, Antans Planutis3, Helen Jung4, Jason Marc Foulks, PhD5, Jinny Lee, PhD6, John O. Mascarenhas, MD7, Ronald Hoffman, MD8
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Sumitomo Pharma América, Marlborough, Massachusetts, United States
6 Sumitomo Pharma América, Marlborough, Massachusetts, United States
7 Icahn School of Medicine at Mount Sinai, New York, New York, United States
8 Icahn School of Medicine at Mount Sinai, New York, New York, United States

Background Myelofibrosis (MF) is characterized by dysplastic megakaryocytes (MKs), and thrombocytopenia (TCP) which occurs in 20-40% of patients and is associated with inferior survival, increased risk for leukemia progression, and limited therapeutic options. Ruxolitinib (RUX), the current standard therapy, frequently exacerbates TCP. PIM1 kinase is downstream of the JAK/STAT and inflammatory pathways and is upregulated following RUX withdrawal and contributes to RUX resistance (PMID 39367172). Nuvisertib (NUVI; TP-3654), a selective oral PIM1 inhibitor, +/-RUX reduces splenomegaly, BM fibrosis and inflammatory gene expression in preclinical MF models while preserving PLT counts (PMID 34741118). In an ongoing Phase 1/2 study, 77 MF patients resistant or ineligible for JAK inhibitor therapy were treated with NUVI (NCT04176198). Median baseline PLT counts were 96×10⁹/L, with 51% of patients having PLT counts <100x10⁹/L. PLT counts remained stable throughout 24 weeks, and 8/30 (26.7%) patients with baseline PLT counts <100x10⁹/L achieved sustained PLT recovery to ≥100x10⁹/L.

The mechanism underlying this PLT-sparing activity remains unknown. We recently demonstrated that TCP MF is characterized by depletion of MK-biased HSCs (CD34+CD38−CD41+), impaired MK maturation and enhanced inflammatory signaling (PMID 40643151). We therefore hypothesized that NUVI sustains productive thrombopoiesis by preserving MK-biased HSCs, promoting Bcl-xL/Mcl-1-dependent MK maturation, and suppressing inflammatory MK cytokine profiles.

Aim To define the cellular and molecular mechanisms underlying the PLT-sparing activity of NUVI and evaluate its ability to overcome defective MF MK maturation.

Methods MKs were generated ex vivo from PBMCs from 9 MF patients (TCP and non-TCP) and 3 healthy donors (HDs) and treated with NUVI, RUX or a pan-PIM inhibitor (PIM-447). MK-biased HSCs (CD34+CD38−CD41+), MK progenitors (CD34+CD41+), mature MKs (CD41+CD42+), DNA ploidy, and MK size were analyzed by flow cytometry and morphology by cytospin. Bcl-xL, Mcl-1, caspase-3 and inflammatory cytokines levels were assessed by Western blot and Meso Scale Discovery platform.

Results In HD-derived cultures, NUVI preserved MK maturation and polyploidization, whereas RUX, like PIM-447, significantly reduced high-ploidy (16N) MKs (18.0±1.5% vs 13.5±1.1%, p=0.003) and increased low-ploidy (2N-4N) MKs (15.6±8.0% vs 33.0±7.4%, p=0.017). NUVI maintained MK progenitors compared with RUX (9.8 x106±3.6x106 vs 0.6x106±0.3x106, p=0.004) and PIM-447 (9.8x106±3.6x106 vs 2.4x106±0.7x106, p=0.011), while preserving large cytoplasmic MKs (LCMs) compared with RUX (60%±11.7 vs 46%±8, p=0.05) and PIM-447 (60%±11.7 vs 34%± 3, p=0.05). NUVI restored LCM formation in a RUX-treated culture, indicating that selective PIM1 inhibition counteracts detrimental effects of JAK inhibition on terminal MK maturation. These effects were associated with preserved Bcl-xL and Mcl-1 expression and limited caspase-3 activation, consistent with productive thrombopoiesis. Navitoclax confirmed the essential role of Bcl-xL in terminal MK maturation by markedly reducing high-ploidy MKs and increasing low-ploidy MKs in both HD and MF cultures. MF-MK cultures exhibited distinct patterns according to TCP status. TCP MF cultures displayed reduced basal Bcl-xL/Mcl-1 expression, accumulation of low-ploidy (2N) MKs, and significantly fewer mature (4N/8N) MKs (2.0x10⁶±0.6x10⁶ vs 1.7x10⁷±8.6x10⁶, p=0.03). NUVI preserved MK-biased HSCs (3.4x107±8.8x106 vs 3.8x107±9.2x106), increased MK size and polyploidization (4N/8N from 13%±3.5% to 37%±7.5%, p=0.007) and restored Bcl-xL and Mcl-1 expression (2-fold and 4-fold, respectively). MKs from a TCP patient secreted high levels of IL-6, IL-8, IL-10, TNF-α, TGF-β1, and YKL-40; NUVI suppressed these inflammatory mediators while improving MK polyploidization. Consistent with these findings, patients in NCT04176198 who achieved PLT recovery exhibited increased circulating tenascin-C and reduced VCAM-1 levels, suggesting reduced inflammation and endothelial activation.

Conclusions NUVI improves megakaryopoiesis in TCP MF by preserving MK-biased HSCs, promoting Bcl-xL/Mcl-1-dependent MK polyploidization and maturation, and suppressing inflammatory MK cytokines. NUVI also preserves normal megakaryopoiesis and mitigates the detrimental effects of JAK inhibition, providing a biological rationale for combining selective PIM1 and JAK inhibition in treating MF patients.

Lilian Varricchio, PhD: No relevant conflicts of interest to declare.